These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 25096734)

  • 1. Development of Web tools to predict axillary lymph node metastasis and pathological response to neoadjuvant chemotherapy in breast cancer patients.
    Sugimoto M; Takada M; Toi M
    Int J Biol Markers; 2014 Dec; 29(4):e372-9. PubMed ID: 25096734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictions of the pathological response to neoadjuvant chemotherapy in patients with primary breast cancer using a data mining technique.
    Takada M; Sugimoto M; Ohno S; Kuroi K; Sato N; Bando H; Masuda N; Iwata H; Kondo M; Sasano H; Chow LW; Inamoto T; Naito Y; Tomita M; Toi M
    Breast Cancer Res Treat; 2012 Jul; 134(2):661-70. PubMed ID: 22689089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A model to predict pathologic complete response of axillary lymph nodes to neoadjuvant chemo(immuno)therapy in patients with clinically node-positive breast cancer.
    Schipper RJ; Moossdorff M; Nelemans PJ; Nieuwenhuijzen GA; de Vries B; Strobbe LJ; Roumen RM; van den Berkmortel F; Tjan-Heijnen VC; Beets-Tan RG; Lobbes MB; Smidt ML
    Clin Breast Cancer; 2014 Oct; 14(5):315-22. PubMed ID: 24548732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nomograms for Predicting Axillary Response to Neoadjuvant Chemotherapy in Clinically Node-Positive Patients with Breast Cancer.
    Vila J; Mittendorf EA; Farante G; Bassett RL; Veronesi P; Galimberti V; Peradze N; Stauder MC; Chavez-MacGregor M; Litton JF; Huo L; Kuerer HM; Hunt KK; Caudle AS
    Ann Surg Oncol; 2016 Oct; 23(11):3501-3509. PubMed ID: 27216742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Nomogram for Predicting the Pathological Response of Axillary Lymph Node Metastasis in Breast Cancer Patients.
    Jin X; Jiang YZ; Chen S; Shao ZM; Di GH
    Sci Rep; 2016 Aug; 6():32585. PubMed ID: 27576704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of axillary lymph node metastasis in primary breast cancer patients using a decision tree-based model.
    Takada M; Sugimoto M; Naito Y; Moon HG; Han W; Noh DY; Kondo M; Kuroi K; Sasano H; Inamoto T; Tomita M; Toi M
    BMC Med Inform Decis Mak; 2012 Jun; 12():54. PubMed ID: 22695278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nomograms for preoperative prediction of axillary nodal status in breast cancer.
    Dihge L; Bendahl PO; Rydén L
    Br J Surg; 2017 Oct; 104(11):1494-1505. PubMed ID: 28718896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early assessment of axillary response with ¹⁸F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla.
    Koolen BB; Valdés Olmos RA; Wesseling J; Vogel WV; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Vrancken Peeters MJ
    Ann Surg Oncol; 2013 Jul; 20(7):2227-35. PubMed ID: 23456316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of longitudinal CT-based radiomics and clinicopathological features predicts the pathological complete response of metastasized axillary lymph nodes in breast cancer.
    Wang J; Tian C; Zheng BJ; Zhang J; Jiao DC; Qu JR; Liu ZZ
    BMC Cancer; 2024 May; 24(1):549. PubMed ID: 38693523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nomogram for predicting axillary upstaging in clinical node-negative breast cancer patients receiving neoadjuvant chemotherapy.
    Maimaitiaili A; Chen H; Xie P; Liu Z; Ling R; Zhao Y; Yang H; Liu Y; Liu K; Zhang J; Mao D; Yu Z; Liu Y; Fu P; Wang J; Jiang H; Zhao Z; Tian X; Cao Z; Wu K; Song A; Jin F; He J; Fan Z; Zhang H
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):8769-8778. PubMed ID: 37129606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Refining the Performance of Sentinel Lymph Node Biopsy Post-neoadjuvant Chemotherapy in Patients with Pathologically Proven Pre-treatment Node-positive Breast Cancer: An Update for Clinical Practice.
    El Hage Chehade H; Headon H; Kasem A; Mokbel K
    Anticancer Res; 2016 Apr; 36(4):1461-71. PubMed ID: 27069121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological factors and nomograms predicting nonsentinel lymph node metastases after neoadjuvant chemotherapy in breast cancer patients.
    Gimbergues P; Abrial C; Durando X; Le Bouedec G; Cachin F; Penault-Llorca F; Mouret-Reynier MA; Kwiatkowski F; Maublant J; Tchirkov A; Dauplat J
    Ann Surg Oncol; 2009 Jul; 16(7):1946-51. PubMed ID: 19408057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can nomograms predict non-sentinel lymph node metastasis after neoadjuvant chemotherapy in sentinel lymph node-positive breast cancer patients?
    Unal B; Gur AS; Ahrendt G; Johnson R; Bonaventura M; Soran A
    Clin Breast Cancer; 2009 May; 9(2):92-5. PubMed ID: 19433389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.
    Cheng J; Wang Y; Mo M; Bao X; Zhang Y; Liu G; Zhang J; Geng D
    Oncotarget; 2015 Oct; 6(30):29388-95. PubMed ID: 26336821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome and pattern of relapse after neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive primary breast cancer.
    Shimizu C; Masuda N; Yoshimura K; Tsuda H; Mano M; Ando M; Tamura K; Fujiwara Y
    Jpn J Clin Oncol; 2009 Aug; 39(8):484-90. PubMed ID: 19477897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ER-poor and HER2-positive: a potential subtype of breast cancer to avoid axillary dissection in node positive patients after neoadjuvant chemo-trastuzumab therapy.
    Li JW; Mo M; Yu KD; Chen CM; Hu Z; Hou YF; Di GH; Wu J; Shen ZZ; Shao ZM; Liu GY
    PLoS One; 2014; 9(12):e114646. PubMed ID: 25504233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab.
    Hsiang DJ; Yamamoto M; Mehta RS; Su MY; Baick CH; Lane KT; Butler JA
    Arch Surg; 2007 Sep; 142(9):855-61; discussion 860-1. PubMed ID: 17875840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive probability of four different breast cancer nomograms for nonsentinel axillary lymph node metastasis in positive sentinel node biopsy.
    Gur AS; Unal B; Johnson R; Ahrendt G; Bonaventura M; Gordon P; Soran A
    J Am Coll Surg; 2009 Feb; 208(2):229-35. PubMed ID: 19228534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for sentinel lymph node metastasis and validation study of the MSKCC nomogram in breast cancer patients.
    Qiu PF; Liu JJ; Wang YS; Yang GR; Liu YB; Sun X; Wang CJ; Zhang ZP
    Jpn J Clin Oncol; 2012 Nov; 42(11):1002-7. PubMed ID: 23100610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of the axilla after neoadjuvant chemotherapy for clinically node positive breast cancer: A nationwide survey study in The Netherlands.
    Vugts G; Maaskant-Braat AJ; de Roos WK; Voogd AC; Nieuwenhuijzen GA
    Eur J Surg Oncol; 2016 Jul; 42(7):956-64. PubMed ID: 27107791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.